GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
Top Cited Papers
Open Access
- 30 March 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 17 (4), 510-524
- https://doi.org/10.1093/humupd/dmr008
Abstract
BACKGROUND GnRH agonist (GnRHa) triggering has been shown to significantly reduce the occurrence of ovarian hyperstimulation syndrome (OHSS) compared with hCG triggering; however, initially a poor reproductive outcome was reported after GnRHa triggering, due to an apparently uncorrectable luteal phase deficiency. Therefore, the challenge has been to rescue the luteal phase. Studies now report a luteal phase rescue, with a reproductive outcome comparable to that seen after hCG triggering. METHODS This narrative review is based on expert presentations and subsequent group discussions supplemented with publications from literature searches and the authors’ knowledge. Moreover, randomized controlled trials (RCTs) were identified and analysed either in fresh IVF cycles with embryo transfer (ET), oocyte donation cycles or cycles without ET; risk differences were calculated regarding pregnancy rate and OHSS rate. RESULTS In fresh IVF cycles with ET (9 RCTs) no OHSS was reported after GnRHa triggering [0% incidence in the GnRHa group: risk difference 5% (with 95% CI: −0.07 to 0.02)]. Importantly, the delivery rate improved significantly after modified luteal support [6% risk difference in favour of the HCG group (95% CI: −0.14 to 0.2)] when compared with initial studies with conventional luteal support [18% risk difference (95% CI: −0.36 to 0.01)]. In oocyte donation cycles (4 RCTs) the OHSS incidence is 0% [10% risk difference (95% CI: 0.02–0.40)]. CONCLUSIONS GnRHa triggering is a valid alternative to hCG triggering, resulting in an elimination of OHSS. After modified luteal support there is now a non-significant difference of 6% in delivery rate in favour of hCG triggering.Keywords
This publication has 115 references indexed in Scilit:
- GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulationReproductive BioMedicine Online, 2010
- A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocolHuman Reproduction, 2009
- A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesteroneFertility and Sterility, 2009
- Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trialJournal of Assisted Reproduction and Genetics, 2009
- No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cyclesFertility and Sterility, 2009
- The incidence of both serious and minor complications in young women undergoing oocyte donationFertility and Sterility, 2008
- The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled studyFertility and Sterility, 2007
- Luteinizing Hormone-Dependent Activation of the Epidermal Growth Factor Network Is Essential for OvulationMolecular and Cellular Biology, 2007
- Functional Properties of Human Vascular Endothelial Cadherin (7B4/Cadherin-5), an Endothelium-Specific CadherinArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndromeThe Lancet, 1994